$RFL
Rafael Holdings, Inc. Stock $rfl

$rfl Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000121390023081589 Filed on October 30, 2023

Income Statement

Concept	2023 Q3	2023	2022 Q3
Revenue	$70.00K	$279.0K	$69.00K
YoY Change	1.45%	-31.95%	-92.88%
Cost Of Revenue
YoY Change
Gross Profit		$279.0K
YoY Change		-109.03%
Gross Profit Margin		100.0%
Selling, General & Admin	$1.400M	$316.8M	$3.048M
YoY Change	-54.07%	1766.21%	-74.71%
% of Gross Profit		113564.52%
Research & Development	$1.270M	$6.312M	$1.841M
YoY Change	-31.02%	-27.8%	17.86%
% of Gross Profit		2262.37%
Depreciation & Amortization	$20.00K	$78.00K	-$1.070M
YoY Change	-101.87%	8.33%	-380.84%
% of Gross Profit		27.96%
Operating Expenses	$2.680M	$323.2M	$4.907M
YoY Change	-45.38%	1156.44%	-64.93%
Operating Profit		-$15.04M
YoY Change		-75.13%
Interest Expense	$4.060M		$193.0K
YoY Change	2003.63%		-60.37%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$1.460M	-$8.745M	-$4.645M
YoY Change	-131.43%	-93.75%	-62.95%
Income Tax	$0.00	-$255.0K	-$6.000K
% Of Pretax Income	0.0%
Net Earnings	$1.220M	-$1.876M	-$4.784M
YoY Change	-125.5%	-98.67%	-61.36%
Net Earnings / Revenue	1742.86%	-672.4%	-6933.33%
Basic Earnings Per Share		-$0.08
Diluted Earnings Per Share	$0.05	-$0.08	-$242.0K
COMMON SHARES
Basic Shares Outstanding		23.26M shares
Diluted Shares Outstanding		23.26M shares

Balance Sheet

Concept	2023 Q3	2023	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$79.21M	$79.50M	$63.24M
YoY Change	25.27%	25.72%	705.13%
Cash & Equivalents	$21.50M	$21.50M	$26.54M
Short-Term Investments	$57.71M	$58.00M	$36.70M
Other Short-Term Assets	$900.0K	$900.0K	$44.67M
YoY Change	-97.98%	-97.98%	648.91%
Inventory
Prepaid Expenses
Receivables	$245.0K	$600.0K	$447.0K
Other Receivables	$1.900M	$1.900M	$0.00
Total Short-Term Assets	$82.94M	$82.90M	$108.3M
YoY Change	-23.45%	-23.49%	633.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.695M	$1.700M	$1.770M
YoY Change	-4.24%	-3.95%	-95.91%
Goodwill
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments	$12.60M	$12.60M	$5.241M
YoY Change	140.41%	140.41%	-93.87%
Other Assets	$9.000K	$0.00	$1.387M
YoY Change	-99.35%	-100.0%	-8.57%
Total Long-Term Assets	$15.89M	$15.90M	$9.973M
YoY Change	59.31%	59.43%	-92.84%
TOTAL ASSETS
Total Short-Term Assets	$82.94M	$82.90M	$108.3M
Total Long-Term Assets	$15.89M	$15.90M	$9.973M
Total Assets	$98.83M	$98.80M	$118.3M
YoY Change	-16.47%	-16.5%	-23.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$333.0K	$400.0K	$564.0K
YoY Change	-40.96%	-36.81%	-56.48%
Accrued Expenses	$763.0K	$800.0K	$1.875M
YoY Change	-59.31%	-57.33%	52.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$15.00M
YoY Change	-100.0%	-100.0%	3.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.145M	$2.100M	$21.03M
YoY Change	-89.8%	-90.01%	21.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$55.00K	$100.0K	$88.00K
YoY Change	-37.5%	13.64%	83.33%
Total Long-Term Liabilities	$55.00K	$100.0K	$88.00K
YoY Change	-37.5%	13.64%	83.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.145M	$2.100M	$21.03M
Total Long-Term Liabilities	$55.00K	$100.0K	$88.00K
Total Liabilities	$2.200M	-$1.500M	$21.11M
YoY Change	-89.58%	-108.42%	-33.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$167.3M		-$165.5M
YoY Change	1.13%		305.54%
Common Stock	$264.0M		$8.000K
YoY Change	3300025.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$100.3M	$100.3M	$100.5M
YoY Change
Total Liabilities & Shareholders Equity	$98.83M	$98.80M	$118.3M
YoY Change	-16.47%	-16.5%	-23.2%

Cashflow Statement

Concept	2023 Q3	2023	2022 Q3
OPERATING ACTIVITIES
Net Income	$1.220M	-$1.876M	-$4.784M
YoY Change	-125.5%	-98.67%	-61.36%
Depreciation, Depletion And Amortization	$20.00K	$78.00K	-$1.070M
YoY Change	-101.87%	8.33%	-380.84%
Cash From Operating Activities	-$1.450M	-$10.89M	-$1.902M
YoY Change	-23.76%	-58.26%	-72.75%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		$85.00K
YoY Change	-100.0%		174.19%
Acquisitions
YoY Change
Other Investing Activities	$7.410M	$21.21M	-$6.462M
YoY Change	-214.67%	-133.25%	-1392.4%
Cash From Investing Activities	$7.410M	$21.21M	-$6.377M
YoY Change	-216.2%	-133.25%	-1300.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-40.00K	-$15.22M	5.997M
YoY Change	-100.67%	-114.65%	-58.72%
NET CHANGE
Cash From Operating Activities	-1.450M	-$10.89M	-1.902M
Cash From Investing Activities	7.410M	$21.21M	-6.377M
Cash From Financing Activities	-40.00K	-$15.22M	5.997M
Net Change In Cash	5.920M	-$5.039M	-2.282M
YoY Change	-359.42%	-136.83%	-128.25%
FREE CASH FLOW
Cash From Operating Activities	-$1.450M	-$10.89M	-$1.902M
Capital Expenditures	$0.00		$85.00K
Free Cash Flow	-$1.450M	-$10.89M	-$1.987M
YoY Change	-27.03%	-58.25%	-71.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-07-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55863
CY2023	dei	Entity Registrant Name EntityRegistrantName	RAFAEL HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2296593
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Broad Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Newark
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07102
CY2023	dei	City Area Code CityAreaCode	(212)
CY2023	dei	Local Phone Number LocalPhoneNumber	658-1450
CY2023	dei	Security12b Title Security12bTitle	Class B common stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	RFL
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	70200000	usd
CY2023	dei	Auditor Firm AuditorFirmId	596
CY2023	dei	Auditor Name AuditorName	CohnReznick LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21498000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26537000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	57714000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	36698000	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	387000	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	140000	usd
CY2023Q3	rfl	Convertible Note Receivable Related Party ConvertibleNoteReceivableRelatedParty	1921000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	245000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	197000	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	213000	usd
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	157000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	914000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4621000	usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	40194000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	294000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	82941000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	108347000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1695000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1770000	usd
CY2023Q3	rfl	In Process Research And Development InProcessResearchAndDevelopment	1575000	usd
CY2022Q3	rfl	In Process Research And Development InProcessResearchAndDevelopment	1575000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1387000	usd
CY2023Q3	us-gaap	Assets Assets	98829000	usd
CY2022Q3	us-gaap	Assets Assets	118320000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	333000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	564000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	763000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1875000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1023000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3518000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	15000000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2145000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21026000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	88000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2200000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	21114000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	264010000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	262023000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167333000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165457000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-353000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-63000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	3725000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	3767000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	100293000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	100515000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-3664000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-3309000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96629000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97206000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98829000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118320000	usd
CY2023	us-gaap	Revenues Revenues	279000	usd
CY2022	us-gaap	Revenues Revenues	410000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8932000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16978000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6312000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8742000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	78000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	72000	usd
CY2022	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit	25000000	usd
CY2022	rfl	Provisionforlossesonrelatedpartyreceivables Provisionforlossesonrelatedpartyreceivables	10095000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-15043000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-60477000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	3253000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	201000	usd
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	334000	usd
CY2022	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	79141000	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	154000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-45000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	309000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	33000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8745000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139972000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-255000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8693000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-140547000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-306000	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-1830000	usd
CY2023	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	6784000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	6478000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1830000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2215000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17719000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1876000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-124658000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2215000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-290000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-63000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-42000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-5000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2547000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-142445000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-336000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-17746000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2211000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-124699000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.36
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.22
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.31
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23263211	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19767342	shares
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97206000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2215000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3091000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	903000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	218000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-290000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-42000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96629000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	136704000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18061000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	18978000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99170000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-6228000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10997000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	75000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-63000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	97206000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2215000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-142377000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	6478000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-1830000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8693000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-140547000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	72000	usd
CY2023	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	220000	usd
CY2022	rfl	Gain Loss On Investments Hedge Fund GainLossOnInvestmentsHedgeFund	-504000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	33000	usd
CY2023	rfl	Unrealized Gain On Investments Cyclo Therapeutics Inc UnrealizedGainOnInvestmentsCycloTherapeuticsInc	-2663000	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	154000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-45000	usd
CY2023	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	1195000	usd
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	334000	usd
CY2022	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals	79141000	usd
CY2022	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit	25000000	usd
CY2022	rfl	Equity In Loss Of Rp Finance2 EquityInLossOfRPFinance2	575000	usd
CY2023	rfl	Equity In Loss Of Day Three Labs Inc2 EquityInLossOfDayThreeLabsInc2	203000	usd
CY2022	rfl	Provision For Losses On Related Party Receivables ProvisionForLossesOnRelatedPartyReceivables	10095000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2188000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	-917000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	117000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-74000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	247000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	140000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-373000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3545000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	27000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-130000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-827000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	52000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	781000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3566000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-43000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-67000	usd
CY2022	rfl	Increase Decrease In Due From Rafael Pharmaceuticals IncreaseDecreaseInDueFromRafaelPharmaceuticals	120000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	15000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	40000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10247000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26038000	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-639000	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-41000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10886000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26079000	usd
CY2022	rfl	Payment To Rafael Pharmaceuticals Pursuant To Line Of Credit PaymentToRafaelPharmaceuticalsPursuantToLineOfCredit	25000000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2022	rfl	Payment To Fund Rp Finance Line Of Credit PaymentToFundRPFinanceLineOfCredit	1875000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	204798000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	65306000	usd
CY2023	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	185121000	usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	28500000	usd
CY2023	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	2000000	usd
CY2023	rfl	Proceeds From Investments Other Pharmaceuticals ProceedsFromInvestmentsOtherPharmaceuticals	78000	usd
CY2023	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	1586000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1325000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3000000	usd
CY2023	rfl	Purchase Of Investment In Cyclo Therapeutics Inc PurchaseOfInvestmentInCycloTherapeuticsInc	2100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-26960000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-63683000	usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	48171000	usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-113000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21211000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63796000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99170000	usd
CY2022	rfl	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty	10997000	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	6228000	usd
CY2023	rfl	Payments For Taxes Related To Shares Withheld For Employee Taxes PaymentsForTaxesRelatedToSharesWithheldForEmployeeTaxes	218000	usd
CY2022	rfl	Payments For Taxes Related To Shares Withheld For Employee Taxes PaymentsForTaxesRelatedToSharesWithheldForEmployeeTaxes	75000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-218000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	103864000	usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-15000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15218000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	103864000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-146000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-306000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5039000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13683000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26537000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12854000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21498000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26537000	usd
CY2023	rfl	Acquisition Of Additional Ownership Interest In Lipo Medix AcquisitionOfAdditionalOwnershipInterestInLipoMedix	16000	usd
CY2022	rfl	Acquisition Of Additional Ownership Interest In Lipo Medix AcquisitionOfAdditionalOwnershipInterestInLipoMedix	8000	usd
CY2023Q1	us-gaap	Debt Current DebtCurrent	2000000	usd
CY2023Q3	us-gaap	Other Ownership Interests Value OtherOwnershipInterestsValue	925000000	usd
CY2023	rfl	Potential Ownership Purchase PotentialOwnershipPurchase	0.95	pure
CY2023	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.42	pure
CY2023	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	0	usd
CY2022	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	575000	usd
CY2020Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	5000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.</p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21500000	usd
CY2023Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current Other AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther	57700000	usd
CY2022Q3	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	33000000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of Credit Risk and Significant Customers </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the year ended July 31, 2023, including revenue from discontinued operations, related parties represented 42% of the Company’s revenue. As of July 31, 2023, there were two customers which represented 27% and 47% of the Company’s accounts receivable balance. For the year ended July 31, 2022, including revenue from discontinued operations, related parties represented 58% of the Company’s revenue, and as of July 31, 2022, two customers, one of which is a related party, represented 24% and 47% of the Company’s accounts receivable balance, respectively.</p>
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4000	usd
CY2020Q4	rfl	Warrants Percentage WarrantsPercentage	0.20	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	22.91
CY2022Q3	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	3225806	shares
CY2022Q3	rfl	Aggregate Price Per Share AggregatePricePerShare	1.86
CY2022Q3	rfl	Aggregtae Sale Price AggregtaeSalePrice	6000000	usd
CY2023Q3	rfl	Aggregate Voting Percentage AggregateVotingPercentage	0.513	pure
CY2022Q3	us-gaap	Property Plant And Equipment Owned Gross PropertyPlantAndEquipmentOwnedGross	49400000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	472000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	70000000	shares
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.03
CY2022Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	49400000	usd
CY2023Q3	us-gaap	Other Notes Payable OtherNotesPayable	15000000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	33000000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	0	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	150000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	1300000	usd
CY2023	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	6800000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	49400000	usd
CY2023	us-gaap	Carrying Costs Property And Exploration Rights CarryingCostsPropertyAndExplorationRights	40200000	usd
CY2023	us-gaap	Other Restructuring Costs OtherRestructuringCosts	1200000	usd
CY2023Q3	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	1200000	usd
CY2019Q1	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	10000000	usd
CY2023	rfl	Percentage Of Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent	0.50	pure
CY2023	rfl	Ownership Interest Percentage OwnershipInterestPercentage	0.08	pure
CY2023	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	17300000	usd
CY2023Q3	us-gaap	Other Minority Interests OtherMinorityInterests	79100000	usd
CY2023	rfl	Interest Amount interestAmount	10400000	usd
CY2023Q1	us-gaap	Impaired Financing Receivable With Related Allowance Unpaid Principal Balance ImpairedFinancingReceivableWithRelatedAllowanceUnpaidPrincipalBalance	2000000	usd
CY2023Q1	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.075	pure
CY2023Q2	us-gaap	Receivable With Imputed Interest Due Dates ReceivableWithImputedInterestDueDates	2023-11-30
CY2023	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.11	pure
CY2023	srt	Interest Bearing Liabilities Average Rate Paid InterestBearingLiabilitiesAverageRatePaid	0.14	pure
CY2023	rfl	Promissory Note Interest Rate1 PromissoryNoteInterestRate1	0.18	pure
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	79000	usd
CY2023	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	54000	usd
CY2023	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	usd
CY2022	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.375	pure
CY2020Q3	us-gaap	Other Commitment OtherCommitment	5000000	usd
CY2020Q4	us-gaap	Other Commitment OtherCommitment	5000000	usd
CY2021Q2	us-gaap	Other Commitment OtherCommitment	10000000	usd
CY2021Q3	us-gaap	Other Commitment OtherCommitment	10000000	usd
CY2021Q3	us-gaap	Other Commitment OtherCommitment	5000000	usd
CY2023	rfl	Cumulative Funds Description CumulativeFundsDescription	the Company has funded a cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance.
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1900000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4764000	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	5268000	usd
CY2023	rfl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisEarnings	220000	usd
CY2022	rfl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisEarnings	-504000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	2000000	usd
CY2023	rfl	Issued And Outstanding Ordinary Shares Percentage IssuedAndOutstandingOrdinarySharesPercentage	0.95	pure
CY2023Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2021-09-01
CY2021Q3	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2021Q4	us-gaap	Share Price SharePrice	0.1878
CY2022Q4	us-gaap	Investment Maturity Date InvestmentMaturityDate	2022-11-11
CY2023Q3	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	8000	usd
CY2023Q1	us-gaap	Share Price SharePrice	0.03
CY2023Q1	us-gaap	Investment Owned Percent Of Net Assets InvestmentOwnedPercentOfNetAssets	0.95	pure
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	16000	usd
CY2023	rfl	Purchase Agreement Description PurchaseAgreementDescription	The Company purchased from Cyclo (i) 2,514,970 common shares (the “Purchased Shares”) and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of $0.71 per share (the “Cyclo Warrant”), at a combined purchase price equal to $0.835 per Purchased Share and Cyclo Warrant to purchase one share, for an aggregate purchase price of $2.1 million.
CY2023Q2	rfl	Additional Shares AdditionalShares	4000000	shares
CY2023Q2	rfl	Warrant Purchase Shares WarrantPurchaseShares	4000000	shares
CY2023Q2	rfl	Aggregate Purchase Amount AggregatePurchaseAmount	5000000000	usd
CY2023Q3	rfl	Purchase Shares PurchaseShares	4000000	shares
CY2023Q3	rfl	Warrant Purchase Shares WarrantPurchaseShares	4000000	shares
CY2023Q3	rfl	Aggregate Purchase Amount AggregatePurchaseAmount	5000000000	usd
CY2023Q4	rfl	Common Shares CommonShares	2514970	shares
CY2023Q4	rfl	Additional Shares AdditionalShares	2766467	shares
CY2023Q4	rfl	Aggregate Purchase Amount AggregatePurchaseAmount	1785629000	usd
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Liability Gain Loss Oci FairValueRecurringBasisUnobservableInputReconciliationAssetLiabilityGainLossOci	-79000	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	6905000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4764000	usd
CY2023Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	100000	usd
CY2022Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	500000	usd
CY2023	rfl	Total Aggregate Fair Value TotalAggregateFairValue	4763102000	usd
CY2023	rfl	Amortized Cost AmortizedCost	59988000	usd
CY2023	rfl	Gross Unrealized Gains GrossUnrealizedGains	4386000	usd
CY2023	rfl	Gross Unrealizedlosses GrossUnrealizedlosses	-4739000	usd
CY2023	rfl	Fair Value FairValue	59635000	usd
CY2022	rfl	Amortized Cost AmortizedCost	36761000	usd
CY2022	rfl	Gross Unrealized Gains GrossUnrealizedGains	81000	usd
CY2022	rfl	Gross Unrealizedlosses GrossUnrealizedlosses	-144000	usd
CY2022	rfl	Fair Value FairValue	36698000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	154000	usd
CY2023Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	69676000	usd
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	41462000	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	334000	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2023Q1	rfl	Amount Of Aggregate Purchase Price AmountOfAggregatePurchasePrice	2100000	usd
CY2023Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	247000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	196000	usd
CY2023Q3	rfl	Accounts Receivable Related Party AccountsReceivableRelatedParty	211000	usd
CY2022Q3	rfl	Accounts Receivable Related Party AccountsReceivableRelatedParty	158000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	245000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	197000	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	213000	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	157000	usd
CY2023	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	388409	shares
CY2022	rfl	Stock Options Excluded From Anti Diluted StockOptionsExcludedFromAntiDiluted	1021277	shares
CY2023	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock	684766	shares
CY2022	rfl	Shares Issuable Upon Vesting Of Restricted Stock SharesIssuableUponVestingOfRestrictedStock	1507373	shares
CY2023	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1073175	shares
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2528650	shares
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8693000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-140547000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-339000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17719000	usd
CY2023	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	-8354000	usd
CY2022	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	-122828000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	6478000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1830000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1876000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-124658000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23263211	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19767342	shares
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.36
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.22
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.31
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	313000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	343000	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	70000	usd
CY2022	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	69000	usd
CY2023Q3	us-gaap	Area Of Land AreaOfLand	80000	sqft
CY2023	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	102000	usd
CY2022Q3	us-gaap	Cash Including Discontinued Operations CashIncludingDiscontinuedOperations	2000000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	720000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	720000	usd
CY2022Q3	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	720000	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	2000000	usd
CY2023Q2	us-gaap	Long Term Debt Maturity Date LongTermDebtMaturityDate	2023-11-30
CY2023Q3	us-gaap	Cash Including Discontinued Operations CashIncludingDiscontinuedOperations	19000	usd
CY2023	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	10000	usd
CY2023	rfl	Revenue Percentage RevenuePercentage	0.42	pure
CY2022	rfl	Revenue Percentage RevenuePercentage	0.58	pure
CY2023Q1	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.95	pure
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1600000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	309000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	63200000	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	40400000	usd
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	7600000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.80	pure
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-6056000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-137978000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2689000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1994000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8745000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139972000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	19000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-274000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-255000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-255000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1877000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	29514000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-479000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-8752000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2958000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35001000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-583000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-459000	usd
CY2022	rfl	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	3632000	usd
CY2023	rfl	Sale Of State No Ls SaleOfStateNOLs	-274000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	92000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	255000	usd
CY2023Q3	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	274000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17852000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15170000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	30236000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	31850000	usd
CY2023Q3	rfl	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	-1000	usd
CY2022Q3	rfl	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	1000	usd
CY2023Q3	rfl	Rd Amortization RDAmortization	689000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	237000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	236000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1858000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1839000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	50871000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	49096000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	50871000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49096000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	683414	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.13
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26982000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	518304	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.54
CY2022	rfl	Weighted Average Remaining Contractual Termin Years Granted WeightedAverageRemainingContractualTerminYearsGranted	P9Y3M
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.53	pure
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.07	pure
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1695000	usd
CY2023Q3	us-gaap	Assets Assets	98829000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1770000	usd
CY2022Q3	us-gaap	Assets Assets	118320000	usd
CY2022	us-gaap	Repayments Of Longterm Loans From Vendors RepaymentsOfLongtermLoansFromVendors	113000	usd
CY2023Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.75
CY2023Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.75
CY2023	rfl	Restricted Stock Units Description RestrictedStockUnitsDescription	On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “Institutional Shares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses.
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	98000000	usd
CY2023	rfl	Deducting Transaction Costs DeductingTransactionCosts	6200000	usd
CY2022Q3	rfl	Aggregate Sale Price AggregateSalePrice	6000000	usd
CY2022Q2	rfl	Employment Agreement Term EmploymentAgreementTerm	P5Y
CY2022Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	600000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	180441	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1021277	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.11
CY2022	rfl	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y5M19D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	175000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.08
CY2023	rfl	Weighted Average Remaining Contractual Termin Years Granted WeightedAverageRemainingContractualTerminYearsGranted	P9Y6M3D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	589205	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	218663	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	388409	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.51
CY2023	rfl	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y8M15D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	65456	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.98
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y1M17D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y5M8D
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	33360	shares
CY2022Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	986835	shares
CY2022Q1	rfl	Restricted Shares Vested Percentage RestrictedSharesVestedPercentage	0.24	pure
CY2022Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	452130	shares
CY2023	us-gaap	Selling Expense SellingExpense	307913000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	915000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1007975	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	46.77
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1533311	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.24
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	90608	shares
CY2022	rfl	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodWeightedAverageGrantDateFairValue	16.86
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	943305	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	48.5
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1507373	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.22
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	220019	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.99
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	745867	shares
CY2023	rfl	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodWeightedAverageGrantDateFairValue	3.37
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	296759	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.1
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	684766	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.04
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	3044000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	17270000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	194000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	791000	usd
CY2023	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative	-931000	usd
CY2022	rfl	Forfeiture Of Rs Us Within General And Administrative ForfeitureOfRSUsWithinGeneralAndAdministrative	-18978000	usd
CY2023	rfl	Forfeiture Of Rs Us Within Research And Development ForfeitureOfRSUsWithinResearchAndDevelopment	-119000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2188000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-917000	usd
CY2023	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	22.91
CY2023	rfl	Lease Expiration Dates LeaseExpirationDates	The Company is the lessor of the Israeli property which is leased to tenants under net operating leases with a term expiration date within 2025.
CY2023	rfl	Comprehensive Income Loss Net Of Tax Attributable To Noncontrolling Interests ComprehensiveIncomeLossNetOfTaxAttributableToNoncontrollingInterests	300000	usd
CY2022	rfl	Comprehensive Income Loss Net Of Tax Attributable To Noncontrolling Interests ComprehensiveIncomeLossNetOfTaxAttributableToNoncontrollingInterests	300000	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	77000	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	78000	usd
CY2023Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	155000	usd
CY2023	rfl	Related Parties Terminate Leases Description RelatedPartiesTerminateLeasesDescription	A related party has the right to terminate the Israeli lease upon four months’ notice.
CY2023Q3	us-gaap	Deposit Assets DepositAssets	825000	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2023Q3	us-gaap	Partners Capital Account Sale Of Units PartnersCapitalAccountSaleOfUnits	925000	usd
CY2022Q3	rfl	Convertible Note Receivable Related Party ConvertibleNoteReceivableRelatedParty		usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit		usd
CY2023	rfl	Provisionforlossesonrelatedpartyreceivables Provisionforlossesonrelatedpartyreceivables		usd
CY2023	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments		usd
CY2023	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.36
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.22
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.09
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.28
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.31
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19767342	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23263211	shares
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2022	rfl	Unrealized Gain On Investments Cyclo Therapeutics Inc UnrealizedGainOnInvestmentsCycloTherapeuticsInc		usd
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties		usd
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments		usd
CY2023	rfl	Impairment Of Cost Method Investment Rafael Pharmaceuticals ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals		usd
CY2023	rfl	Provision For Loss On Receivable Pursuant To Line Of Credit ProvisionForLossOnReceivablePursuantToLineOfCredit		usd
CY2023	rfl	Equity In Loss Of Rp Finance2 EquityInLossOfRPFinance2		usd
CY2022	rfl	Equity In Loss Of Day Three Labs Inc2 EquityInLossOfDayThreeLabsInc2		usd
CY2023	rfl	Provision For Losses On Related Party Receivables ProvisionForLossesOnRelatedPartyReceivables		usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023	rfl	Increase Decrease In Due From Rafael Pharmaceuticals IncreaseDecreaseInDueFromRafaelPharmaceuticals		usd
CY2023	rfl	Payment To Rafael Pharmaceuticals Pursuant To Line Of Credit PaymentToRafaelPharmaceuticalsPursuantToLineOfCredit		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	rfl	Payment To Fund Rp Finance Line Of Credit PaymentToFundRPFinanceLineOfCredit		usd
CY2022	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable		usd
CY2022	rfl	Proceeds From Investments Other Pharmaceuticals ProceedsFromInvestmentsOtherPharmaceuticals		usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2022	rfl	Purchase Of Investment In Cyclo Therapeutics Inc PurchaseOfInvestmentInCycloTherapeuticsInc		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	rfl	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty		usd
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets		usd
CY2023Q3	us-gaap	Heldtomaturity Securities Debt Maturities Date HeldtomaturitySecuritiesDebtMaturitiesDate
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet		usd
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Liability Gain Loss Oci FairValueRecurringBasisUnobservableInputReconciliationAssetLiabilityGainLossOci		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19767342	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23263211	shares
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.36
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.22
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.09
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.28
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.31
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	rfl	Deferred State Expense Benefit DeferredStateExpenseBenefit		usd
CY2022	rfl	Deferred State Expense Benefit DeferredStateExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies		usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2023	rfl	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences		usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment		usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment		usd
CY2022	rfl	Sale Of State No Ls SaleOfStateNOLs		usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther		usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits		usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross		usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q3	rfl	Aggregate Intrinsic Value Outstanding Granted AggregateIntrinsicValueOutstandingGranted		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022	rfl	Weighted Average Remaining Contractual Termin Years Cancelled Forfeited WeightedAverageRemainingContractualTerminYearsCancelledForfeited
CY2022Q3	rfl	Aggregate Intrinsic Value Cancelled Forfeited AggregateIntrinsicValueCancelledForfeited		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	rfl	Aggregate Intrinsic Value Outstanding Granted AggregateIntrinsicValueOutstandingGranted		usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	rfl	Share Based Compensation Weighted Average Remaining Contractual Termin Years Expired ShareBasedCompensationWeightedAverageRemainingContractualTerminYearsExpired
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023	rfl	Weighted Average Remaining Contractual Termin Years Cancelled Forfeited WeightedAverageRemainingContractualTerminYearsCancelledForfeited
CY2023Q3	rfl	Aggregate Intrinsic Value Cancelled Forfeited AggregateIntrinsicValueCancelledForfeited		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	rfl	Forfeiture Of Rs Us Within Research And Development ForfeitureOfRSUsWithinResearchAndDevelopment		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001713863

Files In Submission

Name	View Source	Status
0001213900-23-081589-index-headers.html	Edgar Link	pending
0001213900-23-081589-index.html	Edgar Link	pending
0001213900-23-081589.txt	Edgar Link	pending
0001213900-23-081589-xbrl.zip	Edgar Link	pending
f10k2023ex21-01_rafaelhold.htm	Edgar Link	pending
f10k2023ex23-1_rafaelhold.htm	Edgar Link	pending
f10k2023ex31-01_rafaelhold.htm	Edgar Link	pending
f10k2023ex31-02_rafaelhold.htm	Edgar Link	pending
f10k2023ex32-01_rafaelhold.htm	Edgar Link	pending
f10k2023ex32-02_rafaelhold.htm	Edgar Link	pending
f10k2023ex4-2_rafaelhold.htm	Edgar Link	pending
f10k2023_rafaelhold.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
f10k2023_rafaelhold_htm.xml	Edgar Link	completed
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rfl-20230731.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rfl-20230731_cal.xml	Edgar Link	unprocessable
rfl-20230731_def.xml	Edgar Link	unprocessable
rfl-20230731_lab.xml	Edgar Link	unprocessable
rfl-20230731_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RFL
Rafael Holdings, Inc. Stock $rfl

2023 Q3 Form 10-K Financial Statement

#000121390023081589 Filed on October 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RFL Rafael Holdings, Inc. Stock $rfl

2023 Q3 Form 10-K Financial Statement

#000121390023081589 Filed on October 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RFL
Rafael Holdings, Inc. Stock $rfl